Phase II study of vinorelbine (NVB) and UFT in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.

被引：0
|
作者：
Anton, A
Puertolas, T
Ramos, M
Barnadas, A
Florian, J
Grande, R
Ribelles, N
Lomas, M
机构：
[1] Hosp Miguel Servet, Zaragoza, Spain
[2] Ctr Oncol, Coruna, Spain
[3] Hosp Germans Trias & Pujol, Badalona, Spain
[4] Hosp Barbastro, Huesca, Spain
[5] Hosp Virgen Victoria, Malaga, Spain
[6] Hosp Infanta Cristina, Badajoz, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
751
引用
收藏
页码：64S / 64S
页数：1
相关论文
共 50 条
  • [21] A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines
    Orphanos, George
    Alexopoulos, Athanasios
    Malliou, Savvoula
    Ioannidis, George
    Ardavanis, Alexandros
    Kandylis, Constantinos
    Stavrakakis, John
    Rigatos, Gerassimos
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (01) : 115 - 121
  • [22] Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines: Final results of a phase I/II study
    Schmid, P.
    Regierer, A.
    Kiewe, P.
    Schippinger, W.
    Greil, R.
    Lehenbauer-Dehm, S.
    Niederle, N.
    Freier, W.
    Van de Velde, H.
    Possinger, K.
    Kuehnhardt, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Oral Vinorelbine in Combination With Capecitabine as a First Line Treatment in Patients (pts) With Metastatic Breast Cancer (MBC) Previously Treated With Anthracyclines ± Taxanes - Preliminary Results of a Multicentric Phase II Trial in Egypt
    Kandil, A.
    Hamada, E.
    Moawad, M.
    El Arab, L. Ezz
    Metwalli, H.
    Bathiouny, M.
    Mourad, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S351 - S351
  • [24] A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
    Campone, M.
    Isambert, N.
    Bourbouloux, E.
    Roche, H.
    Bonneterre, J.
    Milano, G.
    Fumoleau, P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 871 - 879
  • [25] Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study
    Brugnatelli, S
    Riccardi, A
    Danova, M
    Pugliese, P
    Tinelli, C
    Luchena, G
    Bernardo, A
    Giardina, G
    Fava, S
    Montanari, G
    Pedrotti, C
    Poli, AM
    ONCOLOGY REPORTS, 2001, 8 (04) : 801 - 805
  • [26] A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
    M. Campone
    N. Isambert
    E. Bourbouloux
    H. Roché
    J. Bonneterre
    G. Milano
    P. Fumoleau
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 871 - 879
  • [27] A Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines
    Vici, Patrizia
    Di Lauro, Luigi
    Sergi, Domenico
    Foggi, Paolo
    Viola, Giuditta
    Mottolese, Marcella
    Giotta, Francesco
    Fattoruso, Silvia I. S.
    Corsetti, Serena
    Giannarelli, Diana
    Botti, Claudio
    Lopez, Massimo
    ONCOLOGY, 2008, 75 (3-4) : 175 - 181
  • [28] Evolving Approaches to Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes
    Murphy, Conleth G.
    Seidman, Andrew D.
    CLINICAL BREAST CANCER, 2009, 9 : S58 - S65
  • [29] Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
    Schmid, P
    Schippinger, V
    Kiewe, P
    Lange, W
    Preiss, J
    Niederle, N
    Brossart, P
    Freier, W
    Van de Velde, H
    Possinger, K
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S68 - S69
  • [30] Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated with adjuvant taxanes.
    Oguz, Arzu
    Babacan, Taner
    Dizdar, Omer
    Kucukoztas, Nadire
    Rahatli, Samed
    Keskin, Gul Sema Yildiran
    Altundag, Ozden
    Altundag, Kadri
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345